GSK Bexxar Launch Aims To Train 200 Sites By Year-End; AWP Is $32,500
Executive Summary
GlaxoSmithKline and Corixa's launch plan for Bexxar will have more than half of the 350 radiopharmacies in the U.S. trained to administer the non-Hodgkin's lymphoma treatment by year-end